 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Cardinal Health, Inc. (CAH) operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. 
It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical.
The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals.
The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines.
Shares have formed a bullish "flag" following the company's latest earnings report. On August 11th, Cardinal Health reported 4th Quarter June 2022 earnings of $1.05 per share on revenue of $47.1 billion. The consensus earnings estimate was $1.17 per share on revenue of $44.6 billion. Revenue grew 10.6% on a year-over-year basis. Higher share prices are expected.
Entry Point: $69.00
Stop Loss: $65.50
Trading Range: $45.85 to $71.45
Target Price: $76.50
